Results 81 to 90 of about 2,626 (203)

Mixed Signals: T Cells as Architects of IgE Immunity

Immunological Reviews, Volume 339, Issue 1, May 2026.
ABSTRACT Food allergen‐specific IgE can cause significant pathology, yet the pathways that generate pathogenic, high‐affinity IgE remain incompletely understood. Increasing evidence suggests that IgE responses arise from the integration of multiple, and sometimes opposing, T cell–derived cues.
Abigail L. Tierney, Wallace P. Bezerra, Stephanie C. Eisenbarth, Adam Williams   +3 more
wiley   +1 more source

Rapid and long‐lasting remission of refractory Hailey‐Hailey disease by IL‐13 inhibition with tralokinumab

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Oliver Brandt, Stephanie M. Huber, Simon M. Mueller   +2 more
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 841-855, May 2026.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

Efficacy of up to 4 years of tralokinumab in adults with moderate‐to‐severe atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 876-886, May 2026.
AD is a relapsing and remitting skin disease often requiring long‐term treatment. We assessed the long‐term efficacy of tralokinumab in adults with moderate‐to‐severe AD consistently treated for up to 4 years. Treatment with tralokinumab plus optional TCS/TCI provided substantial improvements in AD signs and symptoms, and these improvements were ...
Melinda Gooderham, Mahreen Ameen, H. Chih‐ho Hong, Norito Katoh, Richard G. Langley, Ketty Peris, Kristian Reich, Juan F. Silvestre, Eric Simpson, Thomas Werfel, Le Gjerum, Ann‐Marie Tindberg, Christian Bjerregård Øland, Andrew Blauvelt   +13 more
wiley   +1 more source

Italian S3-guideline on the treatment of atopic eczema – first update, adapted from euroguiDerm by the Italian Society of Dermatology and StD (SIDemaSt), the Italian association of Hospital Dermatologists (aDoI) and the Italian Society of allergological and occupational Dermatology (SIDaPa) [PDF]

The evidence- and consensus-based guideline on atopic eczema, published in JEADV on 18 August 2022 (part 1) and 3 September 2022 (part 2) was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual.
Amato S., Amerio P., Arents B. W., Argenziano G., Aszodi N., Avila Valle G. L., Barbarot S., Bieber T., Brough H. A., Calzavara-Pinton P., Chiricozzi A., Christen-Zach S., Corazza M., Cusano F., Deleuran M., Dittmann M., Dressler C., Fink-Wagner A. H., Flohr C., Fosse N., Gaspar K., Gerbens L. A., Gieler U., Girolomoni G., Gisondi P., Gregoriou S., Kinberger M., Mortz C. G., Naldi L., Nast A., Nygaard U., Patruno C., Pigatto P. D., Quaglino P., Redding M., Rehbinder E. M., Ring J., Rossi M., Serra-Baldrich E., Simon D., Stingeni L., Szala I Z. Z., Szepietowski J. C., Tonon F., Torrelo A., Werfel T., Wollenberg A.   +46 more
core   +4 more sources

Dupilumab and Systemic Hematologic Malignancies: Case Series and Literature Review

JEADV Clinical Practice, Volume 5, Issue 1, Page 171-175, March 2026.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 15%–20% of children and 3%–10% of adults. An increased risk of systemic lymphomas – but not leukemias – has been reported in patients with AD. Dupilumab, a monoclonal IgG4 antibody targeting IL‐4 and IL‐13 signaling, is approved for moderate‐to‐severe AD and is ...
Nello Tommasino, Cataldo Patruno, Francesca di Vico, Maddalena Napolitano   +3 more
wiley   +1 more source

Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report

Clinical, Cosmetic and Investigational Dermatology, 2022
Eva Moennig, Stephan Traidl Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School (MHH), Hannover, GermanyCorrespondence: Eva Moennig, Division of Immunodermatology and Allergy Research ...
Moennig E, Traidl S
doaj  

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, Volume 5, Issue 1, Page 101-116, March 2026.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

Atopic Dermatitis in the Elderly Population [PDF]

, 2023
Acta DermatoVenereologica Atopic dermatitis is a common inflammatory disease with a chronic and relapsing course. Although considered a childhood disease, it is now evident that atopic dermatitis is also common in adulthood and in the elderly ...
Andrea CHIRICOZZI, Giampiero GIROLOMONI, Ketty PERIS, Martina MAURELLI, Paolo GISONDI   +4 more
core  

Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study [PDF]

, efficacy and safety of tralokinumab after 32 and 52weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world ...
Barei, Francesca, Calzavara Pinton, Piergiacomo, Ferrucci, Silvia Mariel, Gambardella, Alessio, Girolomoni, Giampiero, Naldi, Luigi, Pezzolo, Elena, Rossi, Mariateresa, Schena, Donatella   +8 more
core   +1 more source